Moderna Gets $590 Million in Federal Funding

Moderna Gets $590 Million of Federal Funding For Influenza Vaccines
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna confirms $590M award by U.S. for bird flu vaccine development
Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor people with animal exposure.
Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines
Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
As bird flu concerns grow, scientists race to develop new vaccines
As fears grow of a possible bird flu pandemic in humans, the federal government is pouring more money into the development of new vaccines, including an mRNA shot.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
Is Moderna a Bad-News Buy for 2025?
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Stocks to Watch: Walgreens Boots Alliance, Moderna
Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine. The financial package will fund the expansion of ...
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...
bovnews3h
Why Did Argus Give Moderna Inc (MRNA) Stock Hold Rating?
Moderna Inc (MRNA) stock saw a decline, ending the day at $33.76 which represents a decrease of $-1.01 or -2.90% from the prior close of $34.77. The stock opened at $34.75 and touched a low of $33.34 ...